Pharmacometric analyses of alectinib to facilitate approval of the optimal dose for the first-line treatment of anaplastic lymphoma kinase-positive non-small cell lung cancer.

Hsu, Joy C; Jaminion, Felix; Guerini, Elena; Balas, Bogdana; Bordogna, Walter; Morcos, Peter N; Frey, Nicolas

Hsu, Joy C; Jaminion, Felix; Guerini, Elena; Balas, Bogdana; Bordogna, Walter; Morcos, Peter N; Frey, Nicolas.

Affiliation

Hsu JC; Roche Innovation Center, F. Hoffmann-La Roche Ltd, New York, New York, USA.
Jaminion F; Roche Innovation Center, F. Hoffmann-La Roche Ltd, Basel, Switzerland.
Guerini E; Roche Innovation Center, F. Hoffmann-La Roche Ltd, Basel, Switzerland.
Balas B; F. Hoffmann-La Roche Ltd, Basel, Switzerland.
Bordogna W; F. Hoffmann-La Roche Ltd, Basel, Switzerland.
Morcos PN; Roche Innovation Center, F. Hoffmann-La Roche Ltd, New York, New York, USA.
Frey N; Roche Innovation Center, F. Hoffmann-La Roche Ltd, Basel, Switzerland.

CPT Pharmacometrics Syst Pharmacol ; 10(11): 1357-1370, 2021 11.

Article in En | MEDLINE | ID: mdl-34547184

Subject(s)

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Carcinoma, Non-Small-Cell Lung / Lung Neoplasms Type of study: Prognostic_studies Limits: Humans Language: En Journal: CPT Pharmacometrics Syst Pharmacol Year: 2021 Document type: Article Affiliation country: Estados Unidos Country of publication: Estados Unidos

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google